ArticleTranslational cancer research2026
Camrelizumab-induced intranasal hemangioma in a patient with hepatocellular carcinoma: a case report.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Since its launch in China in 2019, camrelizumab has been widely used in various cancer treatments. Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common immune-related adverse event of camrelizumab, typically occurring on the skin. However, RCCEP occurring in rare sites still requires special attention. Case Description: This case report describes a patient with hepatocellular carcinoma (HCC) who developed epistaxis and hemoptysis after treatment with camrelizumab combined with apatinib. After excluding multiple etiologies including lung metastasis of liver cancer, pulmonary diseases, infection, and coagulation dysfunction, nasal endoscopy revealed a polypoid vascular lesion in the right Little's area. Following nasal electrocoagulation for hemostasis and switching to regorafenib combined with atezolizumab, the epistaxis and hemoptysis resolved. During the follow-up process, the patient's positron emission tomography/computed tomography (PET/CT) and second nasal endoscopic examination showed no abnormalities in the nasal structure. It was inferred that the epistaxis and hemoptysis were secondary to an intranasal hemangioma induced by camrelizumab. Conclusions: This case highlights the need to monitor RCCEP in rare sites during camrelizumab therapy, especially when symptoms first appear in atypical locations. RCCEP can generally be relieved after discontinuation. The combination of camrelizumab and apatinib can reduce the occurrence of RCCEP, while thalidomide may be a low-cost drug for relieving RCCEP. There are many treatment options for HCC immunotherapy, but it is still necessary to carefully select the treatment options and monitor and manage adverse events in order to improve the prognosis of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.